STUDIES OF NATURALLY OCCURRING DEFECTS IN RESISTANCE TO INFECTION

天然存在的抗感染缺陷的研究

• 批准号: 7603419
• 负责人: HANS D OCHS
• 金额: $ 0.01万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603419
• 关键词: Antibodies; Antibody Formation; Antigens; Bacteriophages; Blood specimen; Bone Marrow Transplantation; Childhood; Computer Retrieval of Information on Scientific Projects Database; Consent; Defect; Diagnostic; Funding; Grant; Immune; Immune response; Immune system; Immunization; Immunoglobulin Class Switching; Immunoglobulin M; Immunoglobulin Somatic Hypermutation; Immunoglobulin Switch Recombination; Immunoglobulin Therapy; Immunoglobulins; Immunologic Deficiency Syndromes; Individual; Infusion procedures; Injection of therapeutic agent; Institution; Intravenous; Intravenous Immunoglobulins; Investigation; Marrow; Measures; Numbers; Patients; Protocols documentation; Purpose; Research; Research Personnel; Resistance to infection; Resources; Route; Source; Standards of Weights and Measures; T-Lymphocyte; Time; United States Food and Drug Administration; United States National Institutes of Health; Week; reconstitution; response; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this ongoing study is to evaluate the immune status of patients with primary immunodeficiency disorders. One aspect of this investigation, and the only subject of this application, is to measure the antibody responses to the T cell-dependent neoantigen, Bacteriophage phiX174, which allows assessment of antigen clearance, the primary IgM response and the secondary response that determines amplification, class switch recombination and somatic hypermutation. Use of Bacteriophage is, in most instances, diagnostic and rarely research. Since Bacteriophage is controlled by the FDA and has an IND number, we need to obtain consent from all patients independent of its use as a diagnostic tool or as a research tool. The response to Bacteriophage will help us to determine the need for immunoglobulin therapy or, in some cases, for bone marrow transplantation (BMT). Following successful BMT, Bacteriophage phiX174 immunization may be used to determine if the marrow recipient's immune system has been fully reconstituted and if it is safe to give standard childhood immunizations. To assess a "mature" immune response to this T cell-dependent antigen, each patient is immunized with a primary injection followed by booster injections (up to three or four times) with this antigen by the intravenous route. This antigen is especially useful in individuals on IVIG because recall antigens cannot be used if an individual receives immunoglobulin infusions. Our standard protocol requests that samples of blood are obtained for antibody analysis at one, two and four weeks post immunization.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项正在进行的研究的目的是评估原发性免疫缺陷障碍患者的免疫状态。 这项研究的一个方面以及本应用的唯一主题是测量抗T细胞依赖性新抗原的抗体反应，噬菌体PHIX174，该抗体允许评估抗原清除率，主要的IgM响应和确定扩增的二级反应，确定放大，类转换重组和体育型。 在大多数情况下，噬菌体的使用是诊断性的，很少研究。 由于噬菌体由FDA控制并具有IND数字，因此我们需要从所有患者的同意下，而与其用作诊断工具或研究工具无关。 对噬菌体的反应将有助于我们确定对免疫球蛋白疗法的需求，或者在某些情况下是骨髓移植（BMT）。 成功BMT后，可以使用噬菌体PHIX174免疫来确定骨髓受体的免疫系统是否已完全重组，以及是否可以安全地进行标准的儿童免疫。 为了评估对这种T细胞依赖性抗原的“成熟”免疫反应，每位患者通过静脉内途径对这种抗原进行了助推器注射（最多三到四次）的助推器注射（最多三到四次）。 该抗原在IVIG的个体中特别有用，因为如果一个人接受免疫球蛋白输注，则无法使用召回抗原。 我们的标准方案要求在免疫后一，两周和四周获得血液样本进行抗体分析。